U-Systems completes $6.5 million funding round

NewsGuard 100/100 Score

U-Systems, Inc., the leader in automated breast ultrasound technology, announced today the completion of a $6.5 million funding round. The additional capital came exclusively from existing U-Systems investors and affiliates including iD SoftCapital Group, Lumira Capital, PIIH, Radius Ventures, and Sycamore Ventures.

“This funding represents an important confidence vote from our investors. The additional funds will enable us to complete our Pre-Market Approval (PMA) submission to the U.S. Food & Drug Administration (FDA), complete the SOMO-INSIGHT Clinical Study as well as continue development of the next generation automated breast ultrasound system”

"This funding represents an important confidence vote from our investors. The additional funds will enable us to complete our Pre-Market Approval (PMA) submission to the U.S. Food & Drug Administration (FDA), complete the SOMO-INSIGHT Clinical Study as well as continue development of the next generation automated breast ultrasound system," said Ron Ho, president and CEO of U-Systems.

"Ultrasound is a proven tool for the diagnosis and treatment of breast cancer. However, it has not typically been used during the screening process. Several large studies have shown that supplementing mammograms with ultrasound for women with dense breast tissue can increase detection from 48 to 97 percent," added Ho. "New approaches to improve early detection in women with dense breasts are clearly needed. We have dedicated significant time and resources to establishing a solid scientific basis for the use of automated breast ultrasound as a cancer screening tool for women with dense breast tissue."

Source:

 U-Systems

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis